Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: RIP who wrote (884)	5/1/1998 12:13:00 PM
From: RIP	Read Replies (1) \| Respond to of 1476

ANTX Shareholders, I mentioned to Terry that ORVX is working on H-Pylori oral vaccine like ANTX. She said she is well aware of the competition and that their vaccine does not cover the broad spectrum of H-Pylori. I track the competition as I can. Thought I would post this for all to read. LONDON, April 28 (Reuters) - UK biotechnology firm Peptide Therapeutics Group Plc said on Tuesday it is collaborating with Pasteur Merieux-OraVax to develop a vaccine against helicobacter pylori, the major cause of peptic ulcers. Pasteur Merieux-OraVax is a joint venture set up in 1995 between Pasteur Merieux Connaught, part of France's Rhone-Poulenc SA , and OraVax Inc of theUnited States. Under the deal, Pasteur Merieux-OraVax will use Peptide's proprietary oral salmonella typhi oral vaccine delivery system to develop a vaccine against helicobacter pylori, and fund the research programme. "Pasteur Merieux-OraVax is the ideal partner with which to pursue this enormous opportunity to prevent peptic ulcers and gastric cancer where helicobacter pylori is implicated as the causative agent," Peptide's chief executive John Brown said in astatement. Current worldwide sales of anti-ulcer products are about $11billion.